GlassScriptPhysician profile
Laura A Bailey
NPI 1770699019
$14,609.68
in general payments reported to CMS, 2019-2025
57 companies · $2,871 in 2025
The $2,871 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $748 · 2021: $2,061 · 2022: $2,499 · 2023: $2,189 · 2024: $2,785 · 2025: $2,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,843.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,556.92 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $1,369.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,199.82 | 2019-2025 | |
| Lilly USA, LLC | $1,082.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,040.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $872.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $789.25 | 2019-2025 | Evenity, Prolia, Otezla |
| E.R. Squibb & Sons, L.L.C. | $586.16 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $406.69 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $364.08 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $349.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $338.65 | 2019-2025 | |
| Abbott Laboratories | $323.50 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $288.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $278.17 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.